Triple therapy with deferiprone, idebenone and riboflavin in Friedreich's ataxia – open-label trial

Authors

  • J. Arpa,

    Corresponding author
    1. Reference Unit of Hereditary Ataxias and Paraplegias, Departments of Neurology, IdiPAZ, Hospital Universitario La Paz, Madrid, Spain
    • J. Arpa, Department of Neurology, Hospital Universitario, La Paz, 28046 Madrid, Spain

      Tel.: +034917277407

      Fax: +034917277050

      e-mail: jarpag@ctv.es

    Search for more papers by this author
  • I. Sanz-Gallego,

    1. Reference Unit of Hereditary Ataxias and Paraplegias, Departments of Neurology, IdiPAZ, Hospital Universitario La Paz, Madrid, Spain
    Search for more papers by this author
  • F. J. Rodríguez-de-Rivera,

    1. Reference Unit of Hereditary Ataxias and Paraplegias, Departments of Neurology, IdiPAZ, Hospital Universitario La Paz, Madrid, Spain
    Search for more papers by this author
  • F. J. Domínguez-Melcón,

    1. Departments of Cardiology, IdiPAZ, Hospital Universitario La Paz, Madrid, Spain
    Search for more papers by this author
  • D. Prefasi,

    1. Reference Unit of Hereditary Ataxias and Paraplegias, Departments of Neurology, IdiPAZ, Hospital Universitario La Paz, Madrid, Spain
    Search for more papers by this author
  • J. Oliva-Navarro,

    1. Reference Unit of Hereditary Ataxias and Paraplegias, Departments of Neurology, IdiPAZ, Hospital Universitario La Paz, Madrid, Spain
    Search for more papers by this author
  • M. Moreno-Yangüela

    1. Departments of Cardiology, IdiPAZ, Hospital Universitario La Paz, Madrid, Spain
    Search for more papers by this author

Abstract

Objectives

The objective of the study was to test the efficacy, safety and tolerability of triple therapy with deferiprone, idebenone and riboflavin in Friedreich's ataxia (FRDA) patients in a clinical pilot study.

Patients and methods

Patients included in this study were 10 males and three females, 14–61 years of age (average 30.2 ± 12.1), diagnosed with FRDA with normal ventricular function. Patients were treated with triple therapy with deferiprone at 5–25 mg/kg/day, idebenone at 10–20 mg/kg/day and riboflavin at 10–15 mg/kg/day for 15–45 months. The efficacy of this triple therapy was assessed by change from baseline on the scale for the assessment and rating of ataxia (SARA) and by the change from baseline in echocardiogram parameters.

Results

Four patients discontinued due to adverse events (AEs) related with deferiprone. The annual worsening rate (AWR) was estimated in this series as 0.96 (CI 95%: 0.462–1.608) SARA score, whereas AWR for our FRDA cohort was estimated as 2.05 ± 1.23 SARA score. LVMI only decreased by 6.5 g/m2 (6.2%) at the end of the first year of therapy. LVEF remained stable, except in case of three patients.

Conclusion

Our results seem to indicate some uncertain benefit on the neurological and heart functions of this triple therapy in FRDA.

Ancillary